Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis

Table 1 State Transitions - Variable Table

Variable	Value	Reference
Severe to Moderate ARDS	45.0% in 7 days	Bellani et al. 2016 [17]
Moderate to Severe ARDS	12.7% in 7 days	Bellani et al. 2016 [17]
Mild to Moderate ARDS	25.8% in 7 days	Bellani et al. 2016 [17]
Mild to Severe ARDS	4.5% in 7 days	Bellani et al. 2016 [17]
Mild ARDS to Floor/Recovery	60% in 28 days	Bellani et al. 2016 [17]
Severe ARDS Mortality	40.9% in 28 days	Bellani et al. 2016 [17]
Moderate ARDS Mortality	35.0% in 28 days	Bellani et al. 2016 [17]
Mild ARDS Mortality	29.6% in 28 days	Bellani et al. 2016 [17]
Mean Presenting PaO₂/FiO₂ Ratio (mm Hg), ICU-COVID Patients	136 (IQR: 103-234)	Wang et al. 2020 [6]
PaO₂/FiO₂ Ratio (mm Hg), for Salvage Use tPA	60
Mean Improvement PaO₂/FiO₂ Ratio (mm Hg), ICU-ARDS Patients	170 (IQR: 135-225)	Hardaway et al. 2001 [7]
Death or non-fatal disabling stroke following systemic tPA	0.6%	GUSTO-I Trial [18]

ISSN: 1749-7922